Price To Earnings Ratio 196.78 | Sector PE 69.47 |
PB Ratio 7.60 | Sector PB 9.32 |
EPS 2.93 | Dividend Yield 0.20 |
Today's Volume 1.984 M | 5 Day Avg. Volume 3.136 M |
PEG Ratio -2.46 | Market Cap. ₹ 30,580.00 Cr. |
Time | LAURUSLABS | VS | Industry |
---|---|---|---|
1 Day | 0.82% | 0.19% | |
1 Week | 8.08% | 3.31% | |
1 Month | 16.31% | 0.92% | |
6 Months | 28.1% | 22.41% | |
1 Year | 51.63% | 48.28% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 548.32 | Bullish |
20 | 519.15 | Bullish |
30 | 504.62 | Bullish |
50 | 488.47 | Bullish |
100 | 473.21 | Bullish |
200 | 450.04 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 665.69 | 993.90 | 911.10 | ||||
Investing Activities | -822.42 | -996.06 | -914.34 | ||||
Financing Activities | 249.83 | -26.64 | 30.26 | ||||
Net Cash Flow | 93.10 | -28.80 | 27.02 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Laurus Labs | 0.82 | 8.08 | 16.31 | 28.1 | 51.63 |
Advanced Enzyme Tech | -0.36 | -4.67 | -22.41 | 0.59 | 14.32 |
Alembic | 1.66 | 6.55 | 4.98 | 2.76 | 2.76 |
Aster DM Healthcare | 0.53 | 1.16 | 8.71 | 30.54 | 14.36 |
Divi's Laboratories | 1.54 | 4.35 | 6.03 | 38.79 | 67.77 |
Laurus Labs Limited is an Indian pharmaceutical and biotechnology company. The company manufactures active ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, diabetes, asthma and gastroenterology. The company also develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) to other global pharmaceutical companies, and produces specialty ingredients for nutraceuticals, nutraceuticals and cosmetics. The company operates through four business units covering various therapeutic applications, including Generics API, which develops, manufactures and sells APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which develops and manufactures oral solid formulations; Synthesis, which is the main starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which deals with recombinant products.